Eleven Biotherapeutics Secures $20,000,000 Series A Round
Feed Type
Link http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=ddfe2365-b062-4963-8b9d-a6c9ab681623&Preview=1
Date 5/8/2012
Company Name Eleven Biotherapeutics
Mailing Address 215 First Street Cambridge, MA 02142
Company Description Eleven Biotherapeutics secured Series A financing in February 2010, backed by two leading life sciences venture capital firms, Flagship Ventures and Third Rock Ventures.
Proceeds Purposes Proceeds from the financing will be used to advance Eleven’s first program, EBI-005, into clinical development while continuing to advance earlier stage programs generated by its proprietary AMP-Rx product engine.